Table 2.
Baseline characteristics in relation to SVR status for all patients in the mITT group for both phases of the 4RIBC study who received four weeks’ treatment with GLE/PIB + ribavirin.
| SVR (18) | Non SVR (9) | p-Value | |
|---|---|---|---|
| Age, Median (IQR) | 43 (39–46) | 42 (40–44) | 0.8195 |
| Sex (Male/female) | 13/5 | 7/2 | 1.000 |
| Genotype 3/non3 | 10/8 | 1/8 | 0.042 * |
| INFL3 CC/non CC | 5/13 | 1/7 n = 8 |
0.628 |
| Weight in kilograms (IQR) | 79.5 (72–89.5) | 73 (69.2–82) | 0.2365 |
| OAT (IQR) | 9 (50.0) | 5 (55.6) | 1.00 |
| BMI, median (IQR) | 26.4 (23.4–27.1) (n = 17) |
24.9 (21.8–26.7) (n = 8) |
0.4147 |
| Viral load (log10 IU/mL) at treatment initiation, median (IQR) | 5.8 (5.3–6.3) | 6.7 (6.4–7.2) | 0.0045 * |
| Current or past injection use (%) | 16 (88.9) | 8 (88.9) | 1.000 |
| Current or past alcohol use (%) | 10 (55.6) | 6 (66.7) | 0.692 |
| Years since infection, median (IQR) | 21 (15–27) (n = 17) |
23 (21–28) | 0.1309 |
| ALT (IU/L) at baseline median (IQR) | 74.5 (44–112) | 49 (44–60) | 0.1107 |
| Positive HCV RNA week 2 yes/no (%) | 6/10 (37.5) (n = 16) |
2/5 (28.6) (n = 7) |
1.000 |
Abbreviations: Interquartile range (IQR); Body Mass Index (BMI); opioid agonist therapy (OAT); sustained virological response (SVR); alanine aminotransferase (ALT); * p-value below 0.05.